Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS apoC-III Rx · 1 trial · 1 indication
The effect of treatment with ISIS ApoC-III Rx or Placebo on fasting total apoC-III levels.
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Non-extensive PK/non post-prandial |
| Group 2a | EXPERIMENTAL | Extensive PK |
| Group 2b | EXPERIMENTAL | Post-prandial assessment |
| Group 3 | EXPERIMENTAL | Stable dose of fibrate |
| Group 4 | EXPERIMENTAL | Fredrickson Type 1 dyslipidemia |
| Name | Type | Description |
|---|---|---|
| ISIS apoC-III Rx | DRUG | Dose 1 |
| Placebo | DRUG | Dose 1 |
Inclusion Criteria: * Severe hypertriglyceridemia Exclusion Criteria: * HbA1c \>/=9.0%, type 1 diabetes, or history of outpatient insulin use for more than 2 weeks in the last year * Body mass index (BMI) \>40 kg/m2 * History of bariatric surgery or currently on weight loss drugs * Use of oral co...
ISIS apoC-III Rx is an investigational small molecule being developed for the treatment of hypertriglyceridemia, a condition characterized by elevated levels of triglycerides in the blood. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
ISIS apoC-III Rx is designed to target apoC-III, a protein involved in the regulation of triglyceride metabolism. By inhibiting the production of apoC-III, the drug aims to reduce triglyceride levels in patients with hypertriglyceridemia.
ISIS apoC-III Rx is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
ISIS apoC-III Rx is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The drug is being studied for its potential to treat hypertriglyceridemia.
ISIS apoC-III Rx has been studied in one completed Phase 2 clinical trial with the identifier NCT01529424. This trial, titled 'Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia,' enrolled 89 participants and was conducted in the United States and Canada.
Yes, ISIS apoC-III Rx is the same drug as ISIS ApoC-III Rx. The name is sometimes written with different capitalization or spacing, but it refers to the same investigational compound being developed by Ionis Pharmaceuticals for hypertriglyceridemia.